The MAGL inhibitor JZL184 (40 mg/kg) and R-flurbiprofen (9 mg/kg) were purchased from Cayman Chemicals, Ann Arbor, MI; Lumiracoxib (5 mg/kg) from Selleck Chemicals, TX, USA; and LM-4131 (10 mg/kg), was synthesized as previously described29 (link); and were administered via intraperitoneal injection (1 ml/kg DMSO) 3 h before sacrifice. LPS (Sigma-Aldrich, St. Louis, MO), was administered via intraperitoneal injection (10 ml/kg; pyrogen-free saline), with two injections of LPS given, 24 h apart. Four hours after the second injection, mice were treated with JZL184 (40 mg/kg). Mice were sacrificed 3 hours after JZL184 or DMSO injection.
Lumiracoxib
Manufactured by Selleck Chemicals
Sourced in United States
Lumiracoxib is a selective COX-2 inhibitor, a type of non-steroidal anti-inflammatory drug (NSAID). It is used as a pharmaceutical ingredient in the development and research of pain management and inflammation treatments.
Automatically generated - may contain errors
Lab products found in correlation
Lipopolysaccharides (lps), by Merck Group (1 mentions)
Jzl184, by Cayman Chemical (1 mentions)
R flurbiprofen, by Cayman Chemical (1 mentions)
Urb597, by Cayman Chemical (1 mentions)
Tocrisolve, by Bio-Techne (1 mentions)
1 ebio, by Bio-Techne (1 mentions)
Apamin, by Bio-Techne (1 mentions)
Celecoxib, by Cayman Chemical (1 mentions)
Capsazepine, by Cayman Chemical (1 mentions)
4 protocols using lumiracoxib
1
Inhibition of Neuroinflammation Pathways
2
IL-6 Receptor Blockade and COX-2 Inhibition
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To block the IL-6 receptor, the mouse IL-6Rα antibody (R&D Systems, Minneapolis, MN, USA) was added at 1 μg/mL in culture medium 2 h before the addition of the cytokines. To inhibit COX activity, lumiracoxib (SelleckChem, Houston, TX, USA), a selective pharmacological inhibitor of COX-2, was added at 100 μM in its vehicle (0.1% Tween-80) 6 h after the addition of cytokines.
3
Topical Cannabinoid Drug Preparation
4
Pharmacological Modulation of Pain Pathways
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The drugs used were the COX-2 inhibitors, LM-4131 (10 mg/kg), Lumiracoxib (1 mg/kg), and Celecoxib (10 mg/kg), the SK channel antagonist, Apamin (0.4 and 0.8 mg/kg), the SK channel agonist, 1-EBIO (5 mg/kg), the CB1R antagonist, Rimonabant (2 and 5 mg/kg), the CB2R antagonist, SR144528 (3 mg/kg), and the TRPV1 antagonist, Capsazepine (10 mg/kg). Rimonabant and SR144528 were gifts from the National Institute of Mental Health Drug Supply Program. LM-4131 was synthesized as previously described (Hermanson et al., 2013 (link)). Lumiracoxib was obtained from Selleck Chemicals (Houston, TX, USA). Celecoxib and Capsazepine were from Cayman Chemical (Ann Arbor, MI, USA). Apamin and 1-EBIO were from Tocris (Minneapolis, MN, USA). Drugs or vehicle were administered by intraperitoneal injection at a volume of 1 mL/kg in DMSO. Drug pretreatment times were two hours prior to behavioral testing.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!